ECE2014 Poster Presentations Endocrine tumours and neoplasia (99 abstracts)
Role of metformin on recurrence-free survival in neuroendocrine tumors
Francesca Marciello 1 , Roberta Modica 1 , Vincenzo Marotta 1 , Valeria Ramundo 1 , Michela Del Prete 1 , Pasqualina Buonomano 1 , Anna Chiara Carratù 1 , Chiara de Luca di Roseto 1 , Ester Picillo , Annamaria Colao 1 & Antongiulio Faggiano 1,
1University of Naples ‘Federico II’, Naples, Italy; 2National Cancer Institute ‘Fondazione Giovanni Pascale’, Naples, Italy.
Introduction: Recent data suggest that metformin has antineoplastic properties in different type of cancer. Effects of metformin have never been investigated in neuroendocrine tumors (NET).
We aim to determine the role of metformine on recurrence-free survival (RFS) in NET patients.
Materials and methods: A retrospective analysis was conducted comparing NET patients with recent diagnosis (<3 year) of diabetes mellitus (with HbA1c≤7%), treated with metformin (group A) to not diabetic NET patients without metformin (group B) with comparable clinical and pathological characteristics. RFS was evaluated by Kaplan–Meier analysis.
Results: We analysed data from 12 patients in group A (five F, seven M; mean age 62 years, follow-up since diagnosis: 4–173 months) and 24 patients in group B (13 F, 11 M; mean age 57 years, follow-up: 6–149 m). G1 and G2 NET were five and seven in group A, 12 and 12 each in group B. Primary NET was in bronchi (one in group A, two in group B), gastrointestinal tract (four in group A, eight in group B), pancreas (seven in group A, 14 in group B). Five patients in group A and seven in group B had liver metastases at diagnosis. Recurrence rate was lower in group A than in group B (8 vs 42%). Median RFS was not reached in group A, it was 86 months in group B (95% CI:19–153, P<0.05). There were no statistically significant differences in RFS between the two groups according to grading, metastases, NET therapies, other anti-diabetic drugs in association with metformine.
Conclusion: In diabetic NET patients, metformin therapy seems to be associated with improved RFS. Prospective studies are needed to better define the anti-neoplastic role of metformin in NET.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more